SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-23-001698
Filing Date
2023-02-02
Accepted
2023-02-02 16:03:32
Documents
6
Period of Report
2023-02-02

Document Format Files

Seq Description Document Type Size
1 6-K share_consolidation_-_fe.htm 6-K 35375
2 EX-99.1 lmnl-ex99_1.htm EX-99.1 1043
3 EX-99.2 lmnl-ex99_2.htm EX-99.2 19948
4 GRAPHIC img164290822_0.jpg GRAPHIC 937024
5 GRAPHIC img164290822_1.jpg GRAPHIC 1024971
6 GRAPHIC img164290822_2.jpg GRAPHIC 222099
  Complete submission text file 0000950170-23-001698.txt   3062079
Mailing Address 440 ARMAND-FRAPPIER BLVD. SUITE 300 LAVAL A8 H7V 4B4
Business Address 231 DUNDAS STREET EAST BELLEVILLE A6 K8N 1E2 450-781-0115
Liminal BioSciences Inc. (Filer) CIK: 0001351172 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39131 | Film No.: 23580810
SIC: 2834 Pharmaceutical Preparations